The present invention provides an engineered regulatory T cell (Treg) comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen recognition domain which specifically binds to asialoglycoprotein receptor (ASGR). The present invention also provides a method of promoting liver tissue repair and/or regeneration in a subject which comprises the step of administering to the subject an engineered Treg comprising a CAR or a pharmaceutical composition comprising the engineered Treg, wherein the CAR comprises a liver-specific antigen recognition domain.

The present application provides GPC2-specific antibodies and antigen binding fragments thereof. A chimeric antigen receptor (CAR) that specifically binds glypican-2 (GPC2) comprising a GPC2-specific antibody, a transmembrane domain, and an intracellular signaling domain. T cells comprising the disclosed CAR constructs can be used for cancer immunotherapy.

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, chimeric antigen receptors (CARs), immune cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.

Vascularizing cell aggregates or tissue segments in a microfluidic device by filling a chamber within the device with a matrix that allows for endothelial sprouting; creating at least three voids within the matrix, of which at least two outer voids are lumenally connected to separate perfusion paths within the device and at least one additional void is positioned in between the at least two outer voids; endothelializing the at least two outer voids; introducing at least one cell type, matrix material, tissue segment, or combinations thereof into the void between the two outer voids; and using vascular growth factors to induce the endothelial cells to sprout into the matrix until the at least three voids are interconnected by endothelial sprouts.

Disclosed herein are expanded NK cells and methods of using thereof for treating, preventing, reducing, and/or inhibiting a microbial infection.

Provided is an antibody or an antigen-binding fragment thereof, a T cell antigen receptor, an immune cell expressing the T cell antigen receptor (TCR), and a preparation method therefor and the use thereof. The TCR can specifically recognize corresponding pMHC complexes, activate TCR T cells, and produce high-level cytokines IFNγ, IL2, TNFα, significantly kill target cells and prolong the life of tumor-bearing mice.

The present invention departs from using traditional modes of cell-to-cell communication and concerns exerting influence on a first cell or cell population by bringing a second cell or cell population into proximity with the first cell population without the use of mediating diffusible factors. Cell to cell communications traditionally occur by way of a variety of mechanisms including, for example, by direct coupling through gap junctions using antigen presentation or using ligand receptor interactions.

A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).

To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.